Cargando…

Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (CR) to treatment is infrequently reported. C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brandi, Giovanni, Venturi, Michela, De Lorenzo, Stefania, Garuti, Francesca, Frega, Giorgio, Palloni, Andrea, Garajovà, Ingrid, Abbati, Francesca, Saccoccio, Gioconda, Golfieri, Rita, Pantaleo, Maria Abbondanza, Barbera, Maria Aurelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020209/ https://www.ncbi.nlm.nih.gov/pubmed/29941039 http://dx.doi.org/10.1186/s40880-018-0312-1

Ejemplares similares

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
por: De Lorenzo, Stefania, et al.
Publicado: (2018)

The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation
por: Ravaioli, Matteo, et al.
Publicado: (2017)

Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
por: Frega, Giorgio, et al.
Publicado: (2020)

Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
por: Garajová, Ingrid, et al.
Publicado: (2017)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

In Reply
por: Brandi, Giovanni, et al.
Publicado: (2016)

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
por: Al-Sukhun, Sana, et al.
Publicado: (2023)

Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients
por: Jung, Yun Hwa, et al.
Publicado: (2017)

Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature
por: Bongiovanni, Alberto, et al.
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review
por: Maur, Michela, et al.
Publicado: (2017)

Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations
por: Brandi, Giovanni, et al.
Publicado: (2012)

Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
por: She, Longjiang, et al.
Publicado: (2022)

Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients’ T cell ferroptosis
por: Wang, Hao, et al.
Publicado: (2023)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
por: Casadei Gardini, Andrea, et al.
Publicado: (2017)

Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
por: Marinelli, Sara, et al.
Publicado: (2013)

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
por: Berruti, Alfredo, et al.
Publicado: (2014)

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
por: Geng, Rui, et al.
Publicado: (2020)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial
por: Roberto, Michela, et al.
Publicado: (2020)

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
por: Di Federico, Alessandro, et al.
Publicado: (2021)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report
por: Vernmark, Karolina, et al.
Publicado: (2015)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments
por: Brandi, Giovanni, et al.
Publicado: (2019)

Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
por: Vasuri, Francesco, et al.
Publicado: (2023)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer
por: Shi, Min, et al.
Publicado: (2020)

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
por: He, Maiyue, et al.
Publicado: (2023)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
por: Palloni, Andrea, et al.
Publicado: (2023)

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
por: Deiana, Chiara, et al.
Publicado: (2023)

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022)

Metronomics for thymic carcinoma
por: del Toro, Jacobo Muñoz, et al.
Publicado: (2014)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study
por: Cazzaniga, M. E., et al.
Publicado: (2014)

Metronomics: Intrinsic Anakoinosis Modulator?
por: Nicolas, André, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sr4ocotkb3ugaeabvvtd94ani2